Intratubal methotrexate for prevention of persistent ectopic pregnancy after salpingotomy

J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):464-7. doi: 10.1016/s1074-3804(05)60520-8.

Abstract

Study objective: To investigate whether frequency of persistent ectopic pregnancy after linear salpingotomy can be reduced by prophylactic administration of a single intraoperative injection of local methotrexate.

Design: Prospective, randomized, controlled trial (Canadian Task Force classification I).

Setting: University-affiliated hospital.

Patients: Sixty-five women with unruptured ectopic pregnancy.

Intervention: Laparoscopic salpingotomy with or without a single intratubal dose of methotrexate 1 mg/kg.

Measurements and main results: In the prophylaxis group, 22 patients received a single dose of intratubal methotrexate 1 mg/kg after linear salpingotomy; 43 controls had only linear salpingotomy. Six women (14%) in the control group developed persistent ectopic pregnancy, compared with none in the prophylaxis group (p <0.05).

Conclusion: In our opinion, intratubal methotrexate injection during laparoscopic salpingotomy is a practical option for women with unruptured ectopic pregnancy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Abortifacient Agents, Nonsteroidal / administration & dosage*
  • Adult
  • Combined Modality Therapy
  • Fallopian Tube Patency Tests
  • Fallopian Tubes / drug effects*
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Intralesional
  • Methotrexate / administration & dosage*
  • Pregnancy
  • Pregnancy, Ectopic / diagnosis
  • Pregnancy, Ectopic / drug therapy
  • Pregnancy, Ectopic / surgery
  • Pregnancy, Tubal / diagnosis
  • Pregnancy, Tubal / drug therapy*
  • Pregnancy, Tubal / surgery*
  • Primary Prevention / methods
  • Prospective Studies
  • Reference Values
  • Salpingostomy / adverse effects
  • Salpingostomy / methods*
  • Secondary Prevention
  • Treatment Outcome

Substances

  • Abortifacient Agents, Nonsteroidal
  • Methotrexate